周围神经刺激（PNS）解决方案提供商Nervonik在筹集了1300万美元A轮融资，以推进用于慢性疼痛缓解的下一代周围神经刺激技术-动脉网

Nervonik Raises $13 Million in Series A Financing to Advance Next-Generation Peripheral Nerve Stimulation for Chronic Pain Relief

CISION 等信源发布 2025-03-04 21:58



可切换为仅中文







LOS ANGELES

洛杉矶

，

March 4, 2025

2025年3月4日

/PRNewswire/ -- Nervonik, Inc. (Nervonik), a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system, has successfully closed a

/PRNewswire/ -- Nervonik公司（Nervonik），一家正在开发无阿片类药物的周围神经刺激（PNS）系统的医疗设备公司，已成功完成了一轮

$13 million

1300万美元

Series A funding round. The round was led by U.S. Venture Partners (USVP), with participation from Foothill Ventures, Correlation Ventures, and other investors. This funding follows Nervonik's earlier

A轮融资。本轮融资由美国风险合伙人（USVP）领投，Foothill Ventures、Correlation Ventures和其他投资者参与。此次融资紧随Nervonik之前的步伐。

$4.4 million

440万美元

in SAFE and convertible note financings from Shangbay Capital, Camford Capital, Joyance Partners, Life Science Angels, Seraph Group, and other investors.

在来自上湾资本、剑桥资本、Joyance Partners、生命科学天使、Seraph集团及其他投资者的安全且可转换的票据融资中。

The proceeds from this financing will be used to advance Nervonik's clinical studies, accelerate regulatory clearance, and prepare for commercialization efforts aimed at transforming chronic pain treatment.

这笔融资所得将用于推进Nervonik的临床研究，加快监管审批，并为旨在变革慢性疼痛治疗的商业化工作做好准备。

Nervonik recently completed its first-in-human clinical study, demonstrating the potential of its PNS technology to transform chronic pain treatment. Nervonik's proprietary wirelessly powered PNS technology delivers minimally invasive, patient-friendly therapy for personalized pain relief.

Nervonik最近完成了其首次人体临床研究，展示了其PNS技术在慢性疼痛治疗方面的潜力。Nervonik专有的无线供电PNS技术提供了微创、对患者友好的治疗方式，实现个性化的疼痛缓解。

'We are excited to receive this strong support from top institutional investors as we push forward in advancing peripheral nerve stimulation technology,' said

“我们很高兴在推进周围神经刺激技术的过程中获得顶级机构投资者的大力支持，”

Aydin Babakhani

艾丁·巴巴哈尼

, PhD, founder and CEO of Nervonik. 'This financing advances our mission to bring a novel solution to millions of people suffering from chronic pain.'

博士，Nervonik创始人兼首席执行官。“这笔融资推动了我们为数百万慢性疼痛患者带来创新解决方案的使命。”

With chronic pain affecting over 50 million people in the U.S. alone, Nervonik's opioid-free PNS technology will offer a compelling alternative to traditional pain management methods, targeting a multibillion-dollar market opportunity.

仅在美国，慢性疼痛就影响着超过5000万人，Nervonik的无阿片类药物的周围神经刺激（PNS）技术将为传统的疼痛管理方法提供一个引人注目的替代方案，瞄准价值数十亿美元的市场机遇。

About Nervonik

关于Nervonik

Nervonik is a medical device company developing cutting-edge peripheral nerve stimulation (PNS) solutions to treat chronic pain. Leveraging advanced, proprietary, wireless power, and closed-loop sensing technologies, Nervonik is committed to providing minimally invasive, effective, and patient-centric treatment options.

Nervonik是一家医疗设备公司，致力于开发尖端的周围神经刺激（PNS）解决方案以治疗慢性疼痛。通过利用先进的、专有的无线供电和闭环传感技术，Nervonik致力于提供微创、有效且以患者为中心的治疗选择。

Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. For more information, visit .

Nervonik 致力于推进临床研究并实现监管里程碑，以将其创新疗法推向市场。欲了解更多信息，请访问。

www.nervonik.com

。

About U.S. Venture Partners (USVP)

美国风险合伙人（USVP）简介

U.S. Venture Partners (USVP) is a leading Silicon Valley venture capital firm, partnering with entrepreneurs to transform their ideas into world-changing companies. USVP has invested in over 500 companies spanning four decades, including: Box, Cato Networks, Edgewise, Epsagon, Happy Returns, HotelTonight, Human Interest, Imperva, Inari Medical, Inspire Medical Systems, Intersect ENT, Kenna, Medigate, MeetMe, Omada Health, Pluto TV, Primary, Smartling, Supplyframe, Standard Bariatrics, ThreatMetrix, Trunk Club, Trusteer and Yammer.

美国风险投资伙伴公司（USVP）是一家领先的硅谷风险投资公司，与企业家合作将其创意转化为改变世界的公司。USVP在四十年间投资了500多家公司，包括：Box、Cato Networks、Edgewise、Epsagon、Happy Returns、HotelTonight、Human Interest、Imperva、Inari Medical、Inspire Medical Systems、Intersect ENT、Kenna、Medigate、MeetMe、Omada Health、Pluto TV、Primary、Smartling、Supplyframe、Standard Bariatrics、ThreatMetrix、Trunk Club、Trusteer和Yammer。

USVP focuses on early-stage start-ups that transform cybersecurity, enterprise software, consumer and healthcare. The USVP team consists of former entrepreneurs, technologists, corporate executives, and financial professionals who assist with strategy, scaling, team building, product development, and business development.

USVP专注于早期初创企业，这些企业正在变革网络安全、企业软件、消费和医疗保健领域。USVP团队由前企业家、技术专家、企业高管和金融专业人士组成，他们在战略、扩展、团队建设、产品开发和业务发展方面提供帮助。

USVP is based in .

USVP 总部位于。

Menlo Park, California

加利福尼亚州门洛帕克

.. For more information, visit

欲了解更多信息，请访问

www.usvp.com

。

SOURCE Nervonik Inc.

来源：Nervonik公司

WANT YOUR COMPANY'S NEWS